Amicus Therapeutics (FOLD) reported $169.06 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 19.5%. EPS of $0.17 for the same period compares to $0.10 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $164.76 million, representing a surprise of +2.61%. The company delivered an EPS surprise of +41.67%, with the consensus EPS estimate being $0.12.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Amicus Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic net product sales- Ex-U.S.: $98.79 million versus $100.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.
- Geographic net product sales- U.S.: $70.27 million compared to the $64.47 million average estimate based on two analysts. The reported number represents a change of +25.1% year over year.
- Net product sales- Pombiliti + Opfolda: $30.71 million versus $29.77 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +45.3% change.
- Net product sales- Galafold: $138.35 million versus the four-analyst average estimate of $150.1 million. The reported number represents a year-over-year change of +14.9%.
View all Key Company Metrics for Amicus Therapeutics here>>>
Shares of Amicus Therapeutics have returned +10.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
